PCOS Is Now PMOS: What the Name Change Means
The 14-year journey to a new name
- In May 2026, the Endocrine Society and 55 partner organizations announced the official rename of PCOS to PMOS at the European Congress of Endocrinology in Prague.
- The new name was published the same day in The Lancet, with a companion paper documenting the underlying research.
- The renaming process took 14 years and involved more than 22,000 patient survey responses across multiple international workshops.
- Patient advocacy groups, endocrinologists, gynecologists, dermatologists, and primary care providers all contributed to the consensus.
Why "polycystic" was scientifically misleading
- Recent imaging research found no significant increase in ovarian cysts among women with the condition compared to controls.
- The "cysts" historically described are actually antral follicles that simply stop maturing into a dominant ovulatory follicle.
- For decades, the original name led patients and even some clinicians to focus on the ovaries, missing the broader endocrine and metabolic features.
- Studies estimate that 70 percent of cases are driven by insulin resistance, while inflammation, stress axis dysregulation, and post-pill recovery contribute to the rest.
What PMOS actually stands for
- P — Polyendocrine: multiple endocrine systems are involved, including insulin, sex hormones, and stress hormones.
- M — Metabolic: blood sugar regulation, lipid balance, and weight regulation are central features for most women with the condition.
- O — Ovarian: the ovaries are still affected, but as a downstream consequence rather than a root cause.
- S — Syndrome: a cluster of features that vary by individual, not a single disease with one mechanism.
Does the rename change treatment?
- No. Clinical guidelines for diagnosis and management remain unchanged in the short term.
- The rename validates the modern shift toward metabolic-focused treatment: insulin sensitizers, anti-inflammatory support, and methylation cofactors.
- Women already managing PMOS with metformin, inositol, NAC, berberine, vitamin D, or methylated B-complex can continue without changes.
- ICD-10 codes are expected to be updated over the next 12 to 18 months. In the meantime, providers will likely use both PCOS and PMOS interchangeably.
What this means for women living with PMOS
- Self-advocacy gets easier — the new name makes clear that this is a hormonal and metabolic condition, not just an ovarian one.
- Insurance coverage should not change. Talk to your provider if you encounter any administrative confusion in the next 12 months.
- Expect more comprehensive workups — endocrinologists may run broader hormone and metabolic panels rather than focusing on ovarian imaging alone.
- The metabolic framing strengthens the case for lifestyle and supplement support alongside any prescription medication.
Frequently asked questions
Is PCOS officially called PMOS now?
Yes. The Endocrine Society and 55 partner organizations announced the official rename on May 12, 2026. The new name, Polyendocrine Metabolic Ovarian Syndrome, was published in The Lancet that same day.
Do I need to update my diagnosis with my doctor?
No formal action is needed. Both PCOS and PMOS refer to the same condition. ICD-10 codes will be updated by the WHO over the next 12 to 18 months, but in the meantime providers will use both names interchangeably.
Does the rename affect my insurance or prescription coverage?
It should not. Until ICD-10 codes are formally updated, your existing PCOS diagnosis remains valid for insurance, prescription, and clinical purposes.
What changes about treatment?
Nothing in the short term. Guidelines remain the same. The rename reinforces the metabolic framing that already drives most modern treatment protocols — insulin sensitizers, anti-inflammatory support, and methylation cofactors.